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Abstract
Background: International recommendations in favor of screening for vaginal infection in pregnancy are based on
heterogeneous criteria. In most developed countries, the diagnosis of bacterial vaginosis is only recommended for
women with high-risk of preterm birth. The Nugent score is currently used, but molecular quantification tools have
recently been reported with a high sensitivity and specificity. Their value for reducing preterm birth rates and
related complications remains unexplored. This trial was designed to assess the cost-effectiveness of a systematic
screen-and-treat program based on a point-of-care technique for rapid molecular diagnosis, immediately followed
by an appropriate antibiotic treatment, to detect the presence of abnormal vaginal flora (specifically, Atopobium
vaginae and Gardnerella vaginalis) before 20 weeks of gestation in pregnant women in France. We hypothesized
that this program would translate into significant reductions in both the rate of preterm births and the medical
costs associated with preterm birth.
Methods/Design: A multicenter, open-label randomized controlled trial (RCT) will be conducted in which 20
French obstetrics and gynecology centers will recruit eligible pregnant women at less than 20 weeks gestation with
singleton pregnancy and with a low-risk factor for preterm birth. Interventions will include a) an experimental
group that will receive a systematic rapid screen-and-treat program from a point-of-care analysis using a molecular
quantification method and b) a control group that will receive usual care management. Randomization will be in a
1:1 allocation ratio. The primary endpoint that will be assessed over a period of 12 months will be the incremental
cost-effectiveness ratio (ICER) expressed as cost per avoided preterm birth before 37 weeks. Secondary endpoints
will include ICER per avoided preterm birth before 24, 28 and 32 weeks, obstetrical outcomes, neonatal outcomes,
rates of treatment failure and recurrence episodes for positive women. Uncertainty surrounding these estimates will
be addressed using nonparametric bootstrapping and represented using cost-effectiveness acceptability curves. A
total of 6,800 pregnant women will be included.
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Discussion: This appropriate randomized controlled design will provide insight into the cost-effectiveness and
therefore the potential cost savings of a rapid screen-and-treat strategy for molecular abnormal vaginal flora in
pregnant women. National and international recommendations could be updated based on the findings of this study.
Trial registration: ClinicalTrials.gov: NCT02288832 (registration date: 30 October 2014); Eudract: 2014-001559-22.
Keywords: Pregnancy, bacterial vaginosis, preterm birth, screen-and-treat strategy, cost-effectiveness analysis, point-of-
care, molecular diagnosis, antibiotic treatment, randomized controlled trial, Atopobium vaginae, Gardnerella vaginalis
Background
Prematurity is an important cause of death and disabil-
ities of infants and children [1]. The preterm birth rate
was approximately 7.4 % in France in 2010 [2], as ob-
served in other developed countries [3]. The presence of
infection and/or inflammation during pregnancy is not-
ably known as a major risk factor for spontaneous preterm
birth [4–6]. Pregnant women with bacterial vaginosis (BV)
have an increased risk of preterm birth compared to
women without BV, and the risk of preterm birth is higher
if BV occurs in the early stage of pregnancy [5]. Several
bacteria are associated with the diagnosis of BV [7]. How-
ever, BV is always associated with the presence of high
loads of Atopobium vaginae and/or Gardnerella vaginalis
[8, 9]. Our team previously showed that high vaginal
concentrations of A. vaginae and/or G. vaginalis were as-
sociated with a significantly decreased interval between
preterm labor and delivery in high-risk pregnancies
[10, 11]. Therefore, the control of vaginal flora anom-
alies (especially A. vaginae and/or G. vaginalis) in low-
risk populations should be considered as an important
aim, to see whether their treatments might prevent pre-
term birth.
In France, the screening (and treatment) of BV is only
recommended for women with high-risk of preterm
birth [12, 13]. Because BV is asymptomatic in approxi-
mately 50 % of cases [14] and early vaginal infection
during pregnancy induces higher risk of obstetrical com-
plications, one of the measures to prevent preterm birth
should concern a systematic screen-and-treat strategy at
the first stage of pregnancy. The standard diagnostic test
is the Nugent score [13], which is laborious and not eas-
ily reproducible [9]. Such abnormalities have led some
authors to propose new diagnostic tools based on molecu-
lar biological techniques [7, 9, 15, 16]. The molecular ap-
proach based on the quantitative real-time polymerase
chain reaction (qPCR) assay appears to be more reprodu-
cible and reclassifies a large number of flora rated as inter-
mediate or normal on the Nugent score as true BV [6, 17].
Answering cost-effectiveness questions is a critical step
in the translation of technological innovation findings
into decision making at the public policy level. Although
there is a considerable amount of literature on the eco-
nomic consequences of preterm birth, little is known
about the cost-effectiveness of screen-and-treat strategies
for vaginal infection. To date, only one cost-effectiveness
analysis of a simple screen-and-treat program for com-
mon asymptomatic vaginal infections in pregnancy has
been published [18]: it showed cost savings through the
first 6 years of life. In this study, the women were tested
with a vaginal Gram stain and scoring criteria by the
Nugent technique, which does not identify the morpho-
types associated with BV such as A. vaginae, and the
screening was performed in the second trimester of preg-
nancy, which is probably too late to prevent pregnancy
complications.
All these considerations may lead to questions on the
cost effectiveness of a systematic screen-and-treat pro-
gram during the first trimester for flora vaginal anomal-
ies among pregnant women with a low-risk of preterm
birth, taking into account advances in diagnostic tools,
bacteria species targeted and antibacterial treatments.
For this purpose, a multicenter, randomized controlled
study was designated to assess the cost effectiveness of
the innovative screening for A. vaginae and G. vaginalis
vaginal portage using a molecular quantification method
by point-of-care with an appropriate treatment for positive
cases, compared to a usual care strategy in pregnant
women at less than 20 weeks of gestation. Several obstet-
rical and neonatal secondary outcomes are also consid-
ered, as well as rates of treatment failure and recurrence
episodes.
Methods/Design
Design
A multicenter, open-label randomized controlled, two-
parallel group study was designed in which pregnant
women who attend prenatal care consultations before
20 weeks’ gestation at French obstetrics and gynecology
centers are randomized between two management strat-
egies: a systematic vaginosis screen-and-treat strategy
(experimental group) and usual care management (con-
trol group). The study protocol was designed using the
recommendations of the Consolidated Standards of
Reporting Trials (CONSORT) statement and according
to the guidelines of cost-effectiveness studies of the
French Health Authority [Haute Autorité en Santé,
Choix méthodologiques pour l’évaluation économique à
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la HAS http://www.has-sante.fr/portail/jcms/c_1120711/
choix-methodologiques-pour-l-evaluation-economique-a-
la-has]. Timing and phasing after eligibility checks are
shown in Fig. 1.
Partners
This work is supported by an institutional grant from the
French 2014 National Program of Cost-effectiveness Re-
search (Programme de Recherche Médico-Economique,
FINESS number 130789049). The recruiting will take
place in 20 French obstetrics and gynecology centers. The
molecular analyses will be performed in two point-of-care
laboratories. The methodological support will be provided
by the Clinical and Cost-Effectiveness Research Unit
(Assistance Publique - Hôpitaux de Marseille, AP-HM,
France), and the Clinical Investigation Unit (Centre
d’Investigation Clinique, AP-HM, France). The central
pharmacy of AP-HM is in charge of the assignment,
allocation and delivery of the devices. All the details
are provided in Table 1.
Inclusion and exclusion criteria
The details of the inclusion and exclusion criteria are
provided in Table 2. The main inclusion criteria are that
women must have less than 20 weeks of gestation, with
singleton pregnancy, they must be symptomatic or non-
symptomatic with regard to their diagnosis of BV, and
they must not have high-risk factors of preterm birth.
The main exclusion criteria are having known conditions
at the time of recruitment that have either increased risk
of spontaneous preterm birth (previous preterm birth,
uterine malformation, or multiple pregnancy) or that
may need preterm delivery due to medical indication:
hypertension, diabetes, fetal malformation, increased risk
for preeclampsia (or other conditions that the investiga-
tors may consider).
Interventions
Experimental group: screen-and-treat strategy
Pregnant women assigned to the intervention group are
asked for a self-collected vaginal swab at randomization
Fig. 1 Schema of timing and phasing - AuTop Study
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(Time 0). The self-collected vaginal swab has previously
been demonstrated to have high validity and reliability
compared to a practitioner-collected swab [17]. The
swab will be immediately tested for A. vaginae and G.
vaginalis using a systematic point-of-care screening test.
Quantitative molecular analyses will be performed in
laboratories that have experienced and national ac-
creditation to realize point-of-care techniques. The
quantitative real-time PCR (qPCR) method used to
diagnose BV was previously described [11]. The result
is reported as copies of microorganism DNA per 1 mL
of vaginal suspension [9]. According to previous works
[9, 11], BV will be defined by an A. vaginae load ≥ 108
copies/mL and/or a G. vaginalis load ≥ 109 copies/mL.
The conclusion will be feedback of the positive or
negative test result to the practitioner within less than
24 hours. In cases of positive diagnosis, the pregnant
woman will be referred to an obstetrician, and an ap-
propriate antibiotic treatment will be provided. The
first intention for treatment of A. vaginae and G. vagi-
nalis will be azithromycin (single dose, 1 g at day 1
and 1 g at day 3). The second choice for antibiotic
treatment will be amoxicillin 2 g per day during 7 days
in cases of known intolerance of azithromicin. The fol-
lowing procedure for women who are diagnosed posi-
tive is to perform a series of three successive screening
controls until 28 weeks to detect either the failure of
antibiotic treatment or a recurrence (that is, reappear-
ance of bacteria from a control vaginal swab after ther-
apy is stopped) (see Fig. 1). In cases of recurrence or
treatment failure, a new antibiotic treatment will be
provided, based on protocol guidelines (see Fig. 2). For
women with a first negative diagnosis, the usual care
management will be proposed.
Table 1 French partners
Gynecologists Center/department
Pr Florence Bretelle Coordinating investigator. Public academic teaching hospital Nord, Marseille
Dr Hélène Heckenroth Public academic teaching hospital La Conception, Marseille
Dr Raoul Desbriere Private Hospital Saint Joseph, Marseille
Dr Nadia Slim Private Hospital Bouchard, Marseille
Dr Nawal Chenni-Asselah Public hospital, Aubagne
Dr Xavier Danoy Public academic hospital, Aix-en-Provence
Dr Franck Mauviel Public academic hospital, Toulon Sainte Musse
Pr André Bongain Public academic teaching hospital, Nice
Pr Pierre Mares Public academic teaching hospital, Caremeau
Pr Patrick Rozenberg Public academic hospital, Poissy-Saint-Germain
Dr Thomas Schmitz Public academic teaching hospital Robert Debré, Paris
Pr Alexandra Benachi Public academic teaching hospital Antoine Béclère, Clamart
Pr Marie-Victoire Senat Public academic teaching hospital Kremlin-Bicêtre, Kremlin-Bicêtre
Pr Bassam Haddad Public academic hospital, Créteil
Dr Jean-Pierre Ménard Protection Maternelle Infantile, Val de Marne
Pr Gilles Kayem Public academic teaching hospital Armand Trousseau, Paris
Pr Loic Sentilhes Public academic teaching hospital, Angers
Pr Céline Chauleur Public academic teaching hospital, Saint-Etienne
Dr Jean-Luc Volumenie Public academic teaching hospital, Martinique
Dr Philippe Kadhel Public academic teaching hospital, Pointe-à-Pitre
Clinical microbiologists Center/department
Pr Florence Fenollar Fédération de Microbiologie Clinique. Public academic teaching hospital la Timone, Marseille
Dr Valérie Serazin Service de Biologie Médicale - UF de Biologie moléculaire. Public general hospital, CHI Poissy St Germain
Methodology team Center/department
Pr Pascal Auquier Public health, public academic teaching hospital, Marseille
Sandrine Loubière & Cécile Fortanier Health economy, public academic teaching hospital, Marseille
Dr Karine Baumstarck Clinical research unit, public academic teaching hospital, Marseille
Dr Nathalie Lesavre Clinical investigation center, public academic teaching hospital, Marseille
Dr Stéphane Honoré & Dr Anita Cohen Pôle Pharmacie, public academic teaching hospital, Marseille
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Control group: usual care management
No systematic vaginosis screening will be performed on
the women assigned to the control group according to
national and international guidelines [13, 19]. Usual
pregnancy care includes 6 to 8 obstetrical consultations,
no systematic vaginal swab, three ultrasound scans, 1st
trimester Down syndrome screening and blood sampling
for toxoplasmosis, syphilis, rubella, and complete blood
group testing.
Recruitment
Eligible women will be invited to take part in the study
during a routine prenatal consultation planned in the
first trimester of their pregnancy. The women who meet
all the inclusion criteria will be randomized into one of
the two groups after completing the informed consent
form.
Randomization
Computer-generated randomized lists were drawn up
before the beginning of the study, using a permuted
block design, under the responsibility of the clinical re-
search unit (AP-HM). The randomization was stratified
by center (1:1 allocation ratio).
Fig. 2 Schema of treatment algorithm alongside the trial - AuTop Study
Table 2 Selection criteria
Inclusion criteria
Woman≥ 18 years of age
Woman less than 20 weeks of gestation
Woman with singleton pregnancy
Woman without history of preterm birth or late miscarriage
Woman with low-risk factor of preterm birth (absence of diabetes,
systemic lupus erythematosus, treated hypertension, fetal malformation,
cervical conization, or multiple pregnancy)
Woman affiliated to or beneficiary of a social security system
Woman who have signed written informed consent
Exclusion criteria
Woman more than 20 weeks of gestation
Minor woman or woman deprived of their freedom by a court/
administrative decision or woman under legal protection
Woman who present high-risk factor of preterm birth or late
miscarriage
Woman with extrauterine pregnancy
Woman with non-evolutive pregnancy
Woman who have received antibiotic treatment in the week before
inclusion
Woman misunderstanding the written and spoken French language
Subject participating in another biomedical research protocol
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Endpoints
Primary endpoint
The primary endpoint is the incremental cost-effectiveness
ratio (ICER), expressed as the extra cost per additional
preterm birth avoided before 37 weeks. The effectiveness
criterion has been discussed and consensually approved
by all the study’s main partners (gynecologist coordinator
and co-coordinators, biologists, health economist and
methodologist). We can assume that this intermediary cri-
terion properly reflects short- and long-term prognosis of
the children [20, 21].
Secondary endpoints
The secondary endpoints are as follows:
1. ICER per preterm birth avoided before 26, 28, 32
and 34 weeks.
2. Obstetrical outcomes: rates of preterm birth before
26, 28, 32, 34, and 37 weeks of gestation,
spontaneous abortion (between 14-22 weeks), late
miscarriage (between 22-24 weeks), premature
rupture of membranes, severe intrauterine growth
restriction, preterm labor, duration of the woman’s
hospitalization (that is hospitalization for delivery or
preterm labor and potential previous hospitalizations
due to gynecologic complications during pregnancy).
3. Neonatal outcomes: neonatal mortality, neonatal
morbidity (respiratory distress syndrome,
bronchopulmonary dysplasia, necrotizing
enterocolitis, periventricular leukomalacia), transfer
to a neonatal intensive care unit (duration),
mechanical ventilation (duration), congenital
anomalies and duration of the newborn’s
hospitalization.
4. Treatment effectiveness: rate of recurrence (defined
as a positive control vaginal swab using qPCR after
the negativation of a precedent control vaginal
swab), rate of treatment failure (defined as A.
vaginae > 108 copies/mL and/or a G. vaginalis load
≥ 109 copies/mL from a control vaginal swab) and
side effects associated with treatment.
5. Other health care utilization: all the mother’s use of
health care during the whole study period (for
example, gynecologists and general practitioner
consultations, hospital admission, clinical
examinations and medications), as well as health
care for the newborn (including neonatal care,
re-hospitalization, medications, planned and
non-planned consultations with pediatric
practitioner or other specialists).
Data collection and follow-up
All data will be recorded from an electronic case report
form (eCRF) specifically elaborated for the study (eCRF
CleanWEB, Telemedicine Technologies S.A.S., www.
tentelemed.com, 2015) and will be recorded at four
specific study’s times as follows: randomization (T0), base-
line assessment (T1), delivery (T2), and at 6 months after
delivery (T3). All assessments are based either on medical
files (pregnancy and delivery characteristics, obstetrical
and neonatal outcomes), face-to-face questionnaires
(smoking and alcohol habits, personal hygiene, pregnan-
cies history or symptoms, and concomitant treatments
such as treatment with pessary or progesterone), phone
calls (to collect data on vaginal symptoms or potential
side-effects of antibiotic) or self-report (health outcomes
of their infant and health service use during the 6 months
following the initial hospitalization). Details of the data re-
corded at the different times of the study are given in
Table 3.
Pharmaceutical aspects
Experimental drugs, azithromycin 250 mg oral tablets
(ZITHROMAX™) and amoxicillin 500 mg oral capsules
Table 3 Data collection, instruments and assessment times
At randomization (T0) Data on the health status of the participant and pregnancy characteristics will be collected from
medical files of the practitioners. A face-to-face questionnaire will be also completed by all women
and filled out by the midwife/obstetrician to collect specific data on demographics characteristics,
smoking and alcohol habits, previous pregnancies and personal hygiene. The first vaginal swab will
be collected by the practitioner and send to one of the two point-of-care laboratories associated to
the study.
At baseline assessment –
(during screening and treatment phases - T1)
Subsequent vaginal swabs will be realized during either routine pregnancy consultation or at the
woman’s home depending on each participant schedule. In this later case, the sample will be sent by
the women to the referent POC laboratory using a stamped, self-addressed envelope. Symptoms and
potential side effects of antibiotics will be collected via a telephone interview. Participants will be
informed via a phone call for subsequent vaginal swabs and treatment intake if needed.
At delivery (T2) All relevant clinical and obstetrical outcomes during pregnancy will be collected from the medical
files. To complete data collection, a face-to-face interview with women around delivery phase will be
scheduled. All relevant data such as pregnancy complications, hospitalizations, delivery characteristics
(including birth weight, terms at delivery, or fetal death) will be collected.
At 6 months after delivery (T3) Participants will be provided with a questionnaire, on which they will be asked to record all health
outcomes of their infant and associated health service use.
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(CLAMOXYL™), will be packaged and labeled by the
“Unité d’Expertise Pharmaceutique et Recherche Biome-
dicale” pharmaceutical unit of the Hospital Pharmacy of
AP-HM and distributed to the dispensing hospital phar-
macy of each investigating center. At the end of the
study, used and unused treatments will be returned to
the dispensing pharmacy and destroyed.
Sample size
The sample size was calculated from the expected differ-
ential ICER per preterm birth avoided between the two
groups. In accordance with Briggs [22], the following hy-
pothesis is stated: with an expected incremental rate of
preterm birth of 1.3 % (4.3 % in the control group [23]
and 3.0 % in the experimental group), an expected incre-
mental cost of 230 euros (including cost of initial and
following point-of-care tests and cost of treatments for
10 % of the women [24]), and an expected differential
ICER at 22,500 euros corresponding to the avoided cost
of a preterm birth before 37 weeks [25], with an 80 %
statistical power and a threshold for statistical signifi-
cance set at a P value of 0.05, and assuming that a po-
tential 20 % of patients will be lost to follow-up, these
calculations showed that 6,800 patients are needed
(3,400 per group). Considering the potential of inclusion
of each participating center, the inclusion duration will
be planned over a 12-month period. The maximal period
of participation for the included women is 12 months.
Statistical analysis
The data will be analyzed using SPSS version 20.0 soft-
ware. Statistical significance is defined as P < 0.05. The
methodology will be based on the Consolidated Stan-
dards of Reporting Trials Statement (CONSORT, http://
www.consort-statement.org/consort-statement/) [26]. The
full analysis population (including all subjects who will be
randomized and will be at least evaluated at baseline) will
be used in the primary analysis and the per protocol
population (including all subjects who will be ran-
domized and will not have major protocol deviations)
will be used in the secondary analysis to assess the
reliability of the results. Finally, missing data will be
handled where possible using multiple imputations,
and a sensitivity analysis will be performed. No in-
terim analysis is planned.
The normality of the parameters will be estimated
using frequency histograms and the Shapiro test. In case
of nonparametric distribution, the data will be log trans-
formed to obtain a normal distribution or nonparametric
bootstrapping performed for cost data. In accordance
with the distribution of the parameters, the baseline pa-
rameters will be presented separately for the control
group and the experimental group: mean (standard devi-
ation) or median (interquartile range) for continuous
variables, proportions for categorical variables. Then, data
will be compared between the two groups using Student’s
t-test for continuous variables (durations), and chi-square
or Fisher’s exact tests for categorical variables.
Cost-effectiveness analysis
Incremental cost-effectiveness ratios (ICER) will be used
to compare the cost and effectiveness of the experimen-
tal strategy with usual care. The ICER is the ratio of the
difference between groups in costs to the difference in
effectiveness. The difference in effectiveness equals the
number of preterm births averted and is calculated as
the number of preterm births in the screening group
minus the number of preterm births in the control
group. Thus, the ICER provides information on the po-
tential acceptability of the intervention for decision
makers. The costs perspective taken in our economic
analysis is that of the healthcare payer. The time horizon
started from the first prenatal consultation before the
20 weeks of gestation and ended at 6-months of age or
death. The healthcare costs included are those that are
likely to differ across the intervention and control
groups. In our study, these costs are those associated
with: screening using the point-of-care procedure (quan-
titative molecular analysis), control vaginal swabs for
positive women, antibiotic treatments, antenatal hospital
admissions, physicians’ consultations, management of
complications, as well as neonatal costs for full term in-
fants and preterm infants. Unit costs for health service
use will be estimated using data from the French Na-
tional Hospital Database (Programme de médicalisation
des systèmes d’information, PMSI) and the National Tariff.
Treatment costs were obtained from the French register
of pharmaceutical specialties, an online database of infor-
mation on healthcare products. The cost of the POC ana-
lysis using quantitative real-time PCR (qPCR) will be
calculated using micro-costing technique, which is par-
ticularly well suited to evaluating the cost of an emerging
technique [27]. The volume of resources used will be de-
termined by direct observation of each stage of each test-
ing procedure. Fixed and variable costs will be included.
All resources will be valued in 2015/2016 euros, and the
12-month trial means there is no requirement to apply
discounting. As the cost of preterm birth differs signifi-
cantly according to the gestational age at birth [28–30],
we will attempt to address this issue by calculating an
ICER for specific birth gestational ages. Probabilistic
sensitivity analyses, using the non-parametric boot-
strap method, will be carried out to generate mean ex-
pected ICERs and to determine whether uncertainty or
variation in the data used affect the ICERs [31]. In
addition, cost-effectiveness acceptability curves were con-
structed to represent decision uncertainty surrounding
cost-effectiveness estimates [32].
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Ethical aspects, laws and regulations
The study will be conducted in accordance with the
Helsinki declaration and the French laws and regulations
(Code de la Santé Publique, article L.1121-1/Loi de
Santé Publique n°2004-806 du 9 Août 2004 relative à la
politique de santé publique et ses décrets d’application
du 27 Août 2006) and the International Conference on
Harmonization (ICH) E6 Guideline for Good Clinical
Practice. Regulatory monitoring will be performed by
the sponsor. French ethics committee and French drug
and device regulation agency approved conduct of the
AuTop study at all sites (registered number respectively:
Comité de Protection des Personnes Sud Méditerranée,
reference number 14.026 and Agence Nationale de Sécur-
ité du Médicament, reference number 140500A-41). This
trial was registered into the government clinical trials
under the identifier number NCT02288832 (Clinical-
Trials.gov). Written Informed consent will be obtained
from all subjects before inclusion.
Discussion
This is the first large randomized controlled trial asses-
sing the cost-effectiveness of a screen-and-treat program
of molecular flora vaginal anomalies during the first tri-
mester in pregnant women with low risk of preterm
birth. This study was designed specifically to inform
healthcare decision making, in an international context
where the diagnosis of BV in pregnant women and its
subsequent management care are controversial [33–37].
Several reasons could be stressed to explain these diver-
ging opinions.
Firstly, there was a real lack of accuracy of diagnostic
tools at the time of some studies. Most of the studies
cited earlier focused on the Nugent score, which has
some limitations. It must be performed on a fresh swab,
and any delay in transporting the swab makes the test
difficult to perform, its scoring requires experienced mi-
crobiologists to ensure consistency, and some pathogens
associated with BV are not identified by such a tech-
nique, in particular A. vaginae [9]. Recent studies have
demonstrated that molecular biology techniques have
both higher sensitivity and specificity for the diagnosis
of BV [7, 9, 15, 16] compared to the Nugent score and
can detect several bacterial series for BV.
The second point concerns the appropriateness of
antibiotic treatment [13, 19]. The nature of the antibi-
otics (such as metronidazole or clindamycin, pro- or
prebiotics) and their modes of administration (oral ver-
sus vaginal) vary considerably between existing studies.
Few studies have controlled for treatment efficacy [38].
In addition, although the frequency of recurrences after
antibiotic treatment is high (from 28 % to 50 %), de-
pending on the nature of the treatment and the length
of time from its intake [39], most of studies did not
consider this risk of recurrence. In the present project,
we propose to use azithromycin because of its effective-
ness on A. vaginae and G vaginalis with a lifetime that
allows us to reduce the treatment duration and to in-
crease the adherence rate [40].
The third point concerns the delay between BV and
treatment. In cases of late diagnosis, and therefore de-
layed treatment, BV has already been established and
can lead to obstetrical complications involving preterm
birth [41]. In this present study, we have considered that
the point-of-care test will be an interesting approach to
minimize the feedback of the vaginal swab to the practi-
tioner in order to rapidly prescribe the antibiotic treat-
ment in cases where tests are positive. In our trial, the
short window for providing a diagnostic result also ap-
pears essential for minimizing the number of women
lost to follow-up who may benefit from an early anti-
biotic treatment. Indeed, this rate of “lost to follow-up
patients” is important in this disease where asymptom-
atic disease, anxiety and low socioeconomic status are
clearly identified risk factors [9].
Finally, the gestational age at inclusion is the greatest
limitation of previous published studies. Due to the lack
of data concerning the early phase of pregnancy, the au-
thors may have underestimated the effectiveness of a
universal screen-and-treat program in reducing the rate
of “very preterm birth” (28 to 32 weeks). These subdivi-
sions into “very preterm” and “moderate” or “late preterm”
(that is, 32 to less than 37 completed weeks of gestation)
are important since decreasing gestational age is associ-
ated with increasing mortality, intensity of neonatal care
required, and hence increasing costs [42].
The main purpose of AuTop trial is to support at a na-
tionwide level the feasibility, acceptability, and cost-
savings of a routine point-of-care molecular diagnosis at
the first stage of pregnancy. Although it is well known
that the consequences in terms of morbidity and mortal-
ity of preterm birth are important and entail a significant
economic burden, several studies have demonstrated
that a large share of the incremental cost per surviving
preterm infant is represented by neonatal care [43, 44].
The average length of this neonatal care can vary from
3 days to 6 months for very preterm births (including
potential immediate re-hospitalization, programmed con-
sultations and bronchiolitis prevention measures). We
then decided to focus on this time horizon for the cost-
effectiveness analysis.
In Kiss et al. [23], the prevalence of BV was around
7 % in their study population (which included women
without subjective complaints, that is, contractions, vagi-
nal bleeding, or symptoms suggestive of vaginal infec-
tion, or women with multiple pregnancies), with less
than 2.3 % having an obstetric history at inclusion. It
is well known that the ethnic origin influences the
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prevalence of bacterial vaginosis in pregnancy. In Kiss’s
RCT, the population was 98 % white ethnic origin. In our
study population, we will expected less than 65 % for the
white ethnic group, based on our previous RTC conducted
in the same French centers [11]. Consequently, we think
that a prevalence of BV of 10 % in a population with or
without clinical symptoms of BV and well balanced in
terms of ethnic origins is not so optimistic. Our hypoth-
esis of a decrease in the rate of preterm births from 4.3 %
to 3.0 % seems to be a small expected gain in the
rate of preterm births avoided. In fact, a mean differ-
ence of 1.3 % is actually a very large difference for
pregnant women and decision makers, and should be
sufficient to prevent major healthcare expenditure.
Decision analysis is particularly useful when the dif-
ference in outcomes between strategies is small, and
can provide insight into the costs contributing to the
public decision-making process.
Given the need for scientific evidence (in terms of
both efficacy and economic) regarding bacterial vagin-
osis screening in a population with low-risk factors for
preterm birth, our analysis should be useful for clinicians
and other healthcare decision makers involved in man-
aging care of pregnant women.
Trial status
At the time of manuscript submission, the status of the
trial is yet recruiting. The inclusion of participants started
in March 2015.
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